Welcome to our dedicated page for Palatin Tech news (Ticker: PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Tech stock.
Palatin Technologies, Inc. (PTN) generates a steady flow of news as a biopharmaceutical company centered on melanocortin receptor–based therapeutics. News coverage for PTN often highlights updates on its obesity, ocular, and retinal programs, as well as financing events and stock listing developments. Investors and followers can use this page to review how Palatin’s scientific, clinical, and corporate milestones evolve over time.
Recent press releases have focused on obesity program progress, including preclinical and clinical data for the oral MC4R agonist PL7737 and next-generation peptide MC4R agonists. Palatin has reported robust weight loss and favorable safety in preclinical models, Phase 2 data on co-administration of an MC4R agonist with tirzepatide in obese patients, and regulatory designations such as Orphan Drug status for PL7737 in LEPR deficiency–related obesity. These updates provide insight into the company’s efforts to develop mechanism-based obesity therapies.
Palatin news also covers its ocular and retinal pipeline. Releases describe Phase 3 MELODY-1 data for PL9643 in dry eye disease, including responder analyses showing complete symptom resolution across multiple endpoints, and preclinical findings for PL9654 and PL9655 in diabetic retinopathy that demonstrate inflammation resolution, vascular stabilization, and neuroprotection. Announcements related to the company’s collaboration with Boehringer Ingelheim for retinal diseases further illustrate how Palatin seeks to advance its melanocortin platform through partnerships.
On the corporate side, PTN news items detail public offerings, warrant structures, and exchange listing status, including NYSE American delisting proceedings, trading on OTC markets, a 1-for-50 reverse stock split, and the subsequent resumption of trading on NYSE American. For readers tracking PTN, this news feed brings together scientific presentations, clinical trial readouts, collaboration agreements, and capital markets activity in one place, making it easier to follow Palatin’s development trajectory and key disclosures.
Palatin Technologies (PTN) reported its fiscal Q1 2022 results, highlighting significant advances in its melanocortin agonist programs. The company expects to initiate a Phase 3 study for PL9643 in December 2021 and a Phase 2 trial for PL8177 in early 2022. Vyleesi's net revenue surged 98% quarter-over-quarter, reaching $159,482, despite a 13% drop in total prescriptions. Total operating expenses rose to $7.4 million, up from $3.7 million in the prior year. Palatin's cash position stands at $53.4 million, sufficient to cover anticipated expenses through 2022.
Palatin Technologies (NYSE American: PTN) will announce its Q1 FY 2022 operating results on November 15, 2021, before U.S. market opening. A conference call will follow at 9:30 a.m. ET, including a review of results and updates on development programs. The results press release will be issued at 7:30 a.m. ET, with a replay available until November 22, 2021. Interested parties can access the audio webcast through Palatin's website.
Palatin Technologies, Inc. (PTN) reported its fourth quarter and fiscal year results, highlighting a successful Phase 2 trial for PL9643, aimed at treating dry eye disease. The company has a cash position of $60.1 million, expected to support operations through 2022. PL9643’s
Palatin Technologies, Inc. (PTN) announced promising results on melanocortin agonists PL8331 and PL9654 at the 2021 ASRS Annual Meeting. The data showcases protective effects against retinal inflammation in mouse models, highlighting potential treatments for diabetic retinopathy. CEO Carl Spana emphasized ongoing positive results in inflammatory disease models. The presentation, scheduled for October 9, 2021, will feature these findings, reinforcing the company's focus on the melanocortin system's therapeutic applications.
Palatin Technologies, Inc. (PTN) will announce its Q4 and fiscal year end 2021 operating results on September 29, 2021, prior to the market opening. A conference call will follow at 11:00 a.m. ET, providing a review of the operating results and updates on ongoing programs. Investors can access the audio webcast through Palatin's website. This announcement is pivotal as it provides insight into the company's financial performance and strategic direction for potential investors.
Palatin Technologies (NYSE American: PTN) announced its participation at the TIDES USA hybrid conference in Boston from September 20-23, 2021. The company will feature a presentation and two poster presentations focused on its melanocortin peptide research, targeting inflammation. CEO Carl Spana will discuss the development of melanocortin-based therapeutics, while John Dodd will present data on colon inflammation. The presentations aim to showcase potential treatments in inflammatory conditions.
Palatin Technologies, a biopharmaceutical company focused on developing first-in-class medicines, announced that Dr. Carl Spana, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment Virtual Conference from September 13-15, 2021. The company specializes in medications that target melanocortin and natriuretic peptide receptor systems, aiming to address significant unmet medical needs. Palatin's strategy includes developing products and forming marketing collaborations to maximize their commercial potential.
Palatin Technologies (PTN) announced a presentation by CEO Carl Spana at the Eyecelerator@ASCRS Conference in Las Vegas, discussing the role of melanocortins in reducing inflammation and presenting data from a Phase 2 study of PL9643 for dry eye disease (DED). The company is set to initiate a Phase 3 clinical trial in late 2021, with a potential NDA submission in late 2023. Notably, PL9643 demonstrated statistically significant improvements in patient symptomatology and showed excellent ocular tolerability in the Phase 2 study.
Palatin Technologies announced the adjournment of its 2021 Annual Meeting of Stockholders, initially held on June 8 and adjourned to July 8, now rescheduled for August 6. This adjournment is to solicit more proxies for an increase in authorized common stock from 300 million to 400 million shares. Approximately 71% of shares voted supported the proposal, but this was insufficient for approval. The Board believes this increase is vital for capital access to advance development programs and explore strategic opportunities. Stockholders are encouraged to vote before the new meeting date.
FAQ
What is the current stock price of Palatin Tech (PTN)?
What is the market cap of Palatin Tech (PTN)?
